Neuropsychological dysfunction in children with sickle cell disease: The AANPAK project by Hijmans, C.T. et al.
VU Research Portal
Neuropsychological dysfunction in children with sickle cell disease: The AANPAK
project
Hijmans, C.T.; Oirschot, M. M. M.; Heijboer, H.; Peters, M.; Hendriks, C.J.; Last, B.F.;





Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Hijmans, C. T., Oirschot, M. M. M., Heijboer, H., Peters, M., Hendriks, C. J., Last, B. F., Oosterlaan, J.,
Grootenhuis, M. A., & Fijnvandraat, K. (2008). Neuropsychological dysfunction in children with sickle cell
disease: The AANPAK project. Pediatric Clinics Amsterdam, 19(1), 10-12.
http://www.amc.nl/upload/teksten/ekz/PCA-2008--1.pdf
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 27. May. 2021
Volume 19, number 1, 2008
PEDIATRIC CLINICS AMSTERDAM
Editorial
In this issue of Pediatric Clinics Amsterdam we proudly present the papers of the young investigators who were 
selected during the Emma’s Children Hospital scientific symposium 2008 to present their research in a master 
class. Although we are already looking forward to the Emma’s Children Hospital scientific symposium 2009, we 
can also look back on a very successful symposium in 2008. Because of the large number of manuscripts available 
for publication in this issue, the paper written by the winner of the poster prize will be presented in the last 
issue of 2008, to be published in December.
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See full article: Pediatr Res. 63(6):650-5, June 2008, 
and commentary: Verbsky JW and Grossman WJ. RSV 
infection--an immune balancing act: Commentary on 




Respiratory syncytial virus (RSV) is a major res-
piratory pathogen in infants and young children.1 
Although RSV infection is in general limited to the 
upper respiratory tract the disease may progress to 
the lower airways leading to acute hypoxemic respira-
tory failure.  Despite decades of research the exact 
mechanisms that determine the development of severe 
RSV-lower respiratory illness (LRTI) in previously 
healthy children remain unclear.  
One hypothesis proposes that activation of cell death 
pathways directed against RSV-infected cells and/
or uninfected bystander cells contributes to disease 
severity.2 Although regulated cell death or apoptosis 
seems an important mechanism for RSV clearance, 
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Welliver et al. identified marked expression of the 
apoptosis marker caspase-3 in airway epithelium of 
children with fatal RSV-LRTI, suggesting an imbal-
ance in this process.3,4
Granzymes (Gr), serine proteases present in granules 
of effector lymphocytes, are involved in several host 
immune responses, including the activation of cell 
death (apoptotic) and inflammatory pathways.5 Detec-
tion of free extracellular GrA and GrB is considered 
to reflect cytotoxic activation of the cell-mediated 
immune response.6,7
In the present study we hypothesized that severe RSV-
LRTI in children is associated with local activation 
of the granzyme pathway by the cell-mediated host 
immune response. To test this, we investigated extra-
cellular GrA and GrB and cellular expression of GrB in 
the respiratory tract of infants with RSV-LRTI.
 
Methods
Briefly, tracheal aspirate (TA) samples were obtained 
from 23 children with RSV-LRTI and 12 age-matched 
controls without a pulmonary condition. All patients 
were admitted to the intensive care unit for mechani-
cal ventilation (MV) between November 2003 and 
March 2006. Infection with RSV was proved by direct 
immunofluorescence assay (Imagen, DakoCytomation, 
UK) of nasopharyngeal aspirate. Extracellular (activ-
ity of) GrA and GrB, interleukin (IL) -8 and extracel-
lular caspase-cleaved cytokeratin-18 (CK18), a marker 
of epithelial cell apoptosis, were measured using 
(sandwich) immunoassays.
FACS analysis was performed in bronchoalveolar 
lavage fluid (BALF) samples from mechanically 
ventilated children with RSV-LRTI in the winters of 
2006-2008. BALF was obtained by three subsequent in-
stillations of 1 ml/kg of 0.9% saline through a wedged 
suction catheter passed through the endotracheal 
tube. BALF cells were stained with APC-labeled anti-
CD3, PerCPCy5-labeled CD8 or CD4 and FITC-labeled 
anti CD16 and -56. For intracellular GrB staining cells 
were fixed and permeabilized with fixation/permeabi-
lization solution and stained with PE-labeled anti-GrB 
mAb or a PE-labeled isotype control.
Results
Elevated GrA and GrB in TA during severe RSV-LRTI
The median (range) level of GrA in TA on the day of 
start of mechanical ventilation was 0.6 (0.3-14.3) ng/
ml and 11.1 (0.3-98.4) ng/ml in controls and RSV-pa-
tients, respectively (p<0.01, Figure 1A). Likewise, the 
median (range) level of GrB in TA was higher in the 
RSV patients (69.0, 3.1-728.0 ng/ml) as compared to 
the controls (1.7, 0.5-39.6 ng/ml) (p < 0.01, Figure 1B). 
There was a significant correlation between the levels 
of GrA and GrB in TA (Spearman r = 0.67, p<0.001). In 
the RSV patients, the plasma levels of GrA (median 
63.0, range 3.0-180.0 pg/ml) and GrB (median 35.0, 
range 13.0-92.0 pg/ml) on the first day of MV were 
significantly lower than the levels in TA (p<0.001 for 
both comparisons, data not shown).
To ascertain biological activity of GrA and GrB in the 
airways of RSV patients we measured active GrA and 
GrB with enzyme capture assays. There was a signifi-
cant correlation between the levels of active GrA and 
total GrA antigen (Spearman r= 0.82, p < 0.01) (Figure 
2A). In addition, we found a positive correlation 
between GrB activity and total GrB antigen (Spearman 
r= 0.62, p = 0.05) (Figure 2B).
There was a positive correlation between GrA and GrB 
and total WBC counts and IL-8 in TA in the RSV pa-
tients and this correlation tended to be stronger after 
the first days of MV (data not shown).
To study lung epithelial apoptosis in relation to 
extracellular granzymes, we analyzed the correlation 
between GrB and cleaved-CK18 in TA. Cytokeratin-18 
is an epithelium-specific intermediate filament 
protein which is cleaved during apoptosis and may 
be subsequently released from cells into the extracel-
lular space (8). There was no significant correlation 
between GrB and cleaved-CK18 in TA at any time (data 
not shown). 
GrB expression by lymphocytes in BALF
T-cells and NK cells were detected in low numbers 
throughout the course of RSV-LRTI. GrB-positive cells 
were found predominantly among cells within the 
side/forward scatter region of the lymphocyte popula-
tion by FACS analysis. In addition to CD8+ T-cells and 




The main goal of this study was to determine whether 
severe RSV infection in children is associated with 
local activation of the granzyme pathway by the 
cell-mediated host immune response. We report high 
levels of proteolytic active extracellular GrA en GrB 
and marked expression of GrB by T-lymphocytes and 
NK cells in the respiratory tract of children during 
the course of severe RSV-LRTI. The levels of extracel-
lular GrA and GrB correlated with total WBC counts 
and IL-8 levels in the airways after the acute-onset of 
RSV disease, but no association with the epithelium 
apoptosis marker cleaved-CK18 could be demonstrated.
The present study adds to our understanding of cell-
mediated cytotoxic responses during severe RSV-LRTI 
in children. Numerous rodent studies have shown 
that both NK cells and CTLs are recruited to the 
lungs during primary RSV infection.9-11 Graham et 
al. reported that although CTLs are involved in the 
clearance of RSV, depletion of these lymphocytes 
diminishes clinical illness upon exposure to RSV.9 
Treatment of RSV-infected CTL-depleted mice with 
high dose RSV-specific CTLs results in viral clearance, 
but augments lung injury by causing severe haemor-
rhage and neutrophilic infiltration.12 These findings 
suggest that cell-mediated cytotoxic responses play an 
important role in RSV disease pathogenesis in mice, 
but the relevance in humans is unclear. Studies in 
vitro show that CTLs isolated from peripheral blood of 
RSV-infected infants lyse infected autologous target 
cells.13,14 However, Welliver et al. recently reported the 
near absence of CTLs and NK cells in lung tissues from 
nine infants who died of RSV-LRTI.4 Previous analysis 
of BALF samples of RSV-infected children showed 
that a small percentage of the total cells in the lungs 
is CD8-positive.15 Similarly, in the present study we 
found low numbers of T-lymphocytes and NK cells in 
the lungs. However, despite these low cell counts, we 
report high levels of extracellular granzymes and marked GrB expres-
sion in these cell populations in the respiratory tract. 
The activation of the cell-mediated granzyme response in children with 
severe RSV-LRTI raises the possibility that this cell death pathway is 
involved in RSV disease pathogenesis. Direct killing of infected cells 
by granzymes is considered a major host defence mechanism against 
viruses in general. In mice, both GrA and GrB are essential in control-
ling ectromelia and cytomegalovirus infection.16,17 Interestingly, viruses 
have been reported to encode proteins that inhibit granzymes, sug-
gesting pathogen immune evasive adaptations.18,19 On the other hand, 
enhanced death of infected cells and/or bystander cells may contribute 
to the development of disease by causing tissue dysfunction as has 
been suggested for severe inflammatory lung diseases.20-22 Welliver et al. 
found marked expression of caspase-3 in airway epithelium of children 
with fatal RSV-LRTI, a finding consistent with studies performed in 
adult patients with ALI/ARDS.4,23 The study of Welliver et al. suggests 
an imbalance in apoptosis during severe RSV-LRTI, but the involved 
cell death pathways remain unclear. Our findings may point toward 
a role for the granzyme pathway in apoptotic cell death during severe 
RSV-LRTI, but contrary to our expectations, we found no correlation 
between the levels of extracellular GrB and caspase-cleaved CK18 in 
the airways. The release of caspase cleaved CK18 is a surrogate marker 
of epithelial apoptosis but has not been studied extensively in vivo. The 
detection of cleaved CK18 in serum was found to correlate well with tis-
sue damage in patients with hantavirus infection, but it is unclear how 
this protein behaves and reflects epithelial injury in other body fluids, 
including BALF.24 Histological analysis of apoptosis to confirm our data 
is highly preferred but could not be performed in our study for obvious 
ethical reasons.
In addition to CTLs and NK cells, CD4+ T-cells and basophils may ex-
press granzymes.25,26 Recently, neutrophils were also shown to express 
granzymes27, although this has been debated by others.28 In the present 
study, GrB-positive cells were only found among lymphocytes. Our 
finding of GrB expression by CD4+ T-lymphocytes is interesting because 
it suggests that the granzyme pathway may be utilized to modulate im-
mune responses to RSV. Devadas et al. have shown that Th2 cells express 
GrB which induces their own cell death.29 Furthermore, they reported 
that GrB deficient mice have augmented Th2 cytokine responses and 
lung cellular infiltrations in a model of allergic inflammation. Gross-
man et al. have shown that the granzyme pathway is exploited by 
natural T-regulatory cells (CD4+CD25+) against autologous activated CD8+ 
and CD4+ T-cells.30 These findings suggest that granzymes function to 
control immune responses, in addition to their role in direct virus-
infected cell killing. 
In conclusion, severe RSV-LRTI in children is associated with high 
 levels of proteolytic active extracellular GrA and GrB and expression 
of GrB by lymphocytes in the respiratory tract. These findings suggest 
that the granzyme pathway is activated by the local cell-mediated host 
immune response to RSV. Further studies should elucidate the exact 
role of granzymes in the lungs during RSV disease. 
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Figure 1. A-B, levels of GrA and GrB (ng/ml) in TA from children without pulmonary 
condition (controls, n=12) or with RSV-LRTI (n=23) on the day of start of mechanical 
ventilation (MV). Bars represent median values. Dotted lines represent lowest detect-
able levels. * p < 0.01.
Figure 2. A, correlation between the levels (ng/ml) of GrA antigen and active GrA in 
TA (Spearman r = 0.82, p < 0.01). B, correlation between the level of total GrB antigen 
(ng/ml) and GrB proteolytic activity (deltaA per hr) in TA (Spearman r = 0.62, p = 
0.05).
Introduction 
Constipation is a symptom rather than a disease and often constitutes 
a major problem for the child and his family. Up to 84% of functionally 
constipated children suffer from fecal incontinence1 and over one third 
exhibit behavior problems.2,3 
Fearful reactions to defecation and stool withholding behavior are 
common in children with constipation.4-9 Retained stools become 
progressively more difficult and painful to evacuate, leading to fear 
and avoidance of defecation.10,11 This vicious cycle can be described as 
acquired behavior. 
The objective of the present study is to evaluate behavioral therapy 
with laxatives compared to conventional treatment. It was hypoth-
esized that behavioral therapy with laxatives would result in more suc-




Between November 2002 and August 2004, children with functional 
constipation aged 4-18 years referred to the gastrointestinal outpatient 
clinic at the Emma Children’s Hospital were eligible for enrolment. At 
entry, patients had to fulfill at least two of four criteria: defecation 
frequency <3 times per week, fecal incontinence ≥2 times per week, 
passage of large amounts of stool at least once every 7–30 days (large 
enough to clog the toilet) or a palpable abdominal or rectal fecal mass.12
Baseline assessment 
Parents recorded frequency of stools and episodes of fecal incontinence 
in a bowel diary. 
Intervention 
A computer-based system was used to generate a sequence of random 
group assignment for consecutive patients. Conventional treatment (CT) 
and behavioral therapy (BT) consisted of 12 visits during 22 weeks. Both 
interventions employed similar laxative therapy. 
Conventional Treatment 
Children were treated with laxatives by the pediatric gastroenterologist 
and received education which included explanation that symptoms are 
not harmful and are common in children with functional constipa-
tion.13
Protocolized Behavioral Therapy
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developed BT. The basic assumption is that phobic re-
actions related to defecation can be reduced and that 
adequate toileting behavior and appropriate defeca-
tion straining can be (re)acquired by teaching parents 
behavioral procedures and by behavioral play therapy 
with the child.
Clinical Outcomes
Primary outcome measures: 1) defecation frequency 
per week, 2) fecal incontinence frequency per week 
and, 3) successful treatment. Treatment was consid-
ered successful if patients achieved a defecation fre-
quency of ≥3 times per week and a fecal incontinence 
frequency of  
≤1 times per two weeks irrespective of laxative use. 
Secondary outcome measures: 1) stool-withholding 
behavior and, 2) behavior problems measured by the 
Child Behavior Checklist (CBCL/4–18).15 The CBCL 
yields scores for a total problem scale and the ‘broad 
band’ syndrome scales internalizing and externaliz-
ing problems. The internalizing scale consists of items 
covering withdrawn behavior, somatic complaints, 
anxiety and depression. The externalizing scale 
consists of items covering delinquent and aggressive 
behavior. A T-score higher than 63 (90th percentile) 
indicates that a child needs professional help for his 
behavior problems. 15 
A post-treatment assessment took place in each inter-
vention arm during the last visit and six months after 
completion of the 22 week-treatment (follow-up). 
Statistical analysis
Intent-to-treat analyses were carried out. To deter-
mine the effect of treatment on primary and second-
ary outcome measures regression models were fitted 
with the factors treatment (conventional treatment, 
behavioral therapy), time (post-treatment, follow-up), 




A total of 134 patients were assigned to conventional 
treatment or behavioral therapy (Figure 1). During 
treatment 2/64 (3.1%) in the CT group and 9/65 (13.8%) 
in the BT group discontinued intervention (p=.054). 
Baseline characteristics are presented in Table 1. 
Primary outcomes
Baseline data are presented in Table 1. Defecation 
frequency increased from an average of 2.0 stools per 
week to 7.2 in the CT group and 5.4 in the BT group at 
post-treatment. Compared to the BT group, defecation 
frequency in CT was significantly higher (IRR=0.75, 
95% CI=0.59-0.96; p=.021). Planned comparisons 
showed that this effect was mainly caused by a differ-
ence between interventions at post-treatment (7.2 vs. 
5.4; p=.021), and not at follow-up (6.6 vs. 5.3; p=.150). 
Fecal incontinence frequency dropped from an aver-
age of 15 per week at start of the study to 2.1 and 5.0 
per week at post-treatment for CT and BT, respectively. 
From post-treatment to follow-up, fecal incontinence 
frequency increased to an average of 6.4 in CT and 
8.6 in BT. No statistically significant difference was 
found between treatment conditions (p=.135). 
At post-treatment, success rate was higher in CT 
(62.3%) than in BT (51.5%). No statistically significant 
difference between treatments was found, however 
(p=.249). At follow-up, the number of children success-
fully treated declined to 57.3% in CT and 42.3% in BT. 
Again, the difference proved statistically non-signifi-
cant (p=.095). 
Secondary outcomes
Baseline data are presented in Table 1. Stool-withhold-
ing behavior was reduced from baseline to follow-up 
in both treatment conditions; from over two-third of 
the children withholding their stools to 13.8% in CT 
and 10.6% in BT at post-treatment. The proportion of 
children with stool-withholding behavior did not dif-
fer between interventions (p=.654). 
Over one-third of the children exhibited behavior 
problems (CBCL T-score>63) at baseline. At end of 
treatment, this percentage was decreased to 22.8% in 
CT and 21.9% in BT. At follow-up, BT was found to have 
influenced behavior problems significantly by reduc-
ing the proportion of children with these problems to 
11.7% compared to 29.2% in CT (RR=0.42, 95% CI=0.18-
0.96; p=.039). 
The proportion of children with internalizing prob-
lems also declined from an average of 35.8% to 17.3% 
and 18.9% for CT and BT, respectively. At follow-up, 
this proportion increased in CT, but decreased further 
in BT (23.4% vs. 14.0%). However, no statistically sig-
nificant effect was found for the effect of treatment 
condition (p=.600), nor for the influence of behavio-
ral therapy at follow-up (p=.156). 
The proportion of children exhibiting externalizing 
problems changed from an average proportion of 
26.9% to 15.9% in CT and 15.6% in BT at post-treat-
ment. Both treatments appeared equally effective in 
reducing externalizing problems (p=.990).
Conclusion
This study is the first large randomized controlled 
trial evaluating the clinical effectiveness of behavio-
ral therapy with laxatives for functional constipation 
in childhood. The results indicate that this behavioral 
therapy with laxatives has no advantage over conven-
tional treatment in treating childhood constipation. 
However, this study shows that behavioral therapy is 
superior in addressing behavior problems in consti-
pated children. 
Conventional treatment should remain the treatment 
of choice. Behavioral therapy may be considered when 
children concurrently experience behavior problems. 
Quality of care for chronically constipated children 
may be improved by adding a behavioral screening 
to the clinical evaluation of constipated children.(11,16) 
Positive screening should lead to consideration of be-
havioral therapy or referral to mental health services.
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Age, mean (SD), y 6.5 (2.1) 6.9 (2.5) 134 .367
 Boys, No (%) 37 (55.2) 39 (58.2) 134 .727
History
Age of onset constipation, mean (SD), y 3.0 (2.0) 2.8 (1.9) 134 .551
Period of treatment, mean (SD), mo 17.1 (19.4) 18.7 (21.7) 129† .673
 Positive family history, No (%) 28 (43.8) 33 (50.8) 131† .338
Outcome
Defecation frequency/week, mean (SD) 1.9 (2.7) 2.0 (2.3) 134 .961
Fecal incontinence/week, mean (SD) 15.6 (15.9) 15.0 (14.2) 134 .831
Stool-withholding behavior, N (%) 44 (68.8) 43 (67.2) 128† .850
CBCL Total score, N (%)* 26 (38.8) 23 (34.3) 133‡ .591
CBCL Internalizing score, N (%)* 25 (37.3) 23 (34.3) 133‡ .719
CBCL Externalizing score, N (%)* 18 (26.9) 18 (26.9) 133‡ 1.00
Additional clinical symptomatology
Painful defecation, No (%) 39 (65.0) 28 (43.1) 125† .014
Hard stools, No (%) 19 (32.2) 14 (22.2) 122† .215
Large amount of stool, No (%) 46 (68.7) 45 (67.2) 134 .853
Abdominal pain, No (%) 46 (69.7) 46 (68.7) 133† .897
Day time urinary incontinence, No (%) 12 (17.9) 10 (14.9) 134 .641
 Night time urinary incontinence, No (%) 23 (34.3) 19 (28.4) 134 .456
Physical examination
Abdominal scybalus, No (%) 20 (31.3) 22 (35.5) 126§ .614
 Rectal scybalus, No (%) 27 (49.1) 38 (58.5) 120§ .305
Table 1. Baseline characteristics of children allocated to conventional treatment or behavioral therapy.
Abbreviations.  SD: Standard deviation; y: year; mo: month; CBCL: Child Behavior Checklist.
†  Missing characteristics were unknown to parents.
‡ One CBCL questionnaire was not filled out.
§ Missing physical examination, because the child was too anxious to perform examination.
* Proportion children with CBCL T-score >63 (90th percentile)
 
134  randomized
67  allocated to receive Conventional
Treatment
3 did not receive allocated intervention
2 free of complaints
1 declined participation
12  excluded
3 did not meet functional constipation criteria
8 refused to participate
1 loss of contact
67  included in ITT analysis
56 completed 6-months follow-up
 
67  included in ITT analysis
58 completed 6-months follow-up
1 loss of contact
3 research procedure violations
62 completed 22-week treatment
2 discontinued intervention
1 other burden in family
1 severe behavior problems
and/or disturbed parent-child
interaction
64  received Conventional Treatment
56  completed 22-week treatment
9 discontinued intervention
2 other burden in family
2 treatment required too much
effort or time
5 severe behavior problems
and/or disturbed parent-child
interaction
65 received Behavioral Therapy  
2 did not  receive allocated intervention
1 free of complaints
1 declined participation   
67  allocated to receive Behavioral Therapy





















In The Netherlands at least 500,000 (14%) of all children 
grow up with a chronic disease.1 Recent data from the 
United States show that at least 7% (5 million children) 
of all children have a limitation of activity due to a 
health condition, the number of chronically ill chil-
dren being even higher.2 The number of children with 
a chronic disease is likely to increase further due to 
medical improvement, genetic, social and behavioral 
changes.2 For parents, learning that their child has a 
chronic and potentially life threatening disease is a 
very stressful and potentially traumatic event.3 Besides 
emotional impact, having a chronically ill child also 
influences family and social life, as parents provide most 
of the daily care for these children.4,5 The care-giving 
role combined with family life, an occupational career 
and social life can be very stressful for parents.6,7 Parents 
report a lower quality of life and experience physical 
and emotional strain.8,9 Parental physical, emotional and 
social health also influences the health and well-being of 
their children.3,10 This results in a contradictory situation 
as for parents it is becoming more difficult to fulfill all 
tasks, while on the other hand their role in providing 
care is of increasing importance for the health and well-
being of their children.
Analysis of mean scores showed a lower Health Related 
Quality of Life (HRQOL) for parents of chronically ill 
children. In this paper we asses the prevalence of par-
ents with an impaired quality of life based on the 25th 
percentile of the norm population. This information 
will provide insight into the degree of parental HRQOL 




Parents of chronically ill children were recruited be-
tween January 2006 and September 2007 in the Emma 
Children’s Hospital in Amsterdam, The Netherlands, 
and through patient organizations. Chronic illness was 
defined according to Mokkink et al.1,11, including the 
following criteria: the disease occurs in children aged 
0-18 years, the diagnosis is based on medical scientific 
knowledge, is not (yet) curable and has existed for at 
least three months, or will probably continue longer, 
or at least three disease episodes have occurred the last 
year. We selected ten different chronic diseases in child-
hood: asthma, diabetes, Down syndrome, Duchenne’s 
muscular dystrophy, end stage renal disease, metabolic 
diseases, profound multiple handicaps, sickle cell disease, 
spina bifida, and survivors of a brain tumor. Inclusion 
criteria were: (1) the chronically ill children were aged 
between 1-19 years old, (2) were diagnosed >1 year before 
inclusion in the study, (3) the children lived at home (4) 
parents were able to fill out the questionnaire in Dutch 
or English. 
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Parents in the comparison group were eligible if their 
child (1) was not chronically ill, (2) was between 1-19 
years old (3) was living at home (4) parents were able to 
fill out the questionnaire in Dutch or English. 
Procedure
Parents received an introductory letter explaining the 
aim of the study and requesting their participation. 
The letter was accompanied by the questionnaire, an 
informed consent form and a stamped self-addressed 
envelope. The comparison group consisted of parents of 
healthy children from two elementary schools and one 
high school located within 50 kilometers of our hospital. 
The schoolchildren took an envelope home for their 
parents, including the introductory letter, the question-
naire, the informed consent form and the stamped self-
addressed envelope. 
Measurement
HRQOL was assessed with the ‘TNO-AZL Questionnaire 
for Adult’s Health related Quality of Life’ (TAAQOL).12 The 
questionnaire measures health status problems weighted 
by the impact of problems on well-being on 12 multi-item 
scales of which we present six in this paper: sleep, social 
functioning, daily activities, vitality, positive emotions 
and depressive emotions. 
Each item consists of two parts: the first part assesses 
the prevalence of a health problem or limitation in the 
past month, the second part the emotional response to 
the health problem or limitation. Answers were scored 
on 4 point scales. The scales vitality, positive emotions, 
depressive emotions and aggressiveness only assess the 
occurrence of the feelings in the past month. Higher 
scores indicate a better HRQOL. The Cronbach’s alphas in 
the present study were mainly satisfactory to good, rang-
ing from 0.60-0.96. The psychometric properties, validity 
and reliability, of the TAAQOL were satisfactory.12 
Statistical analysis
First, scales were constructed and missing data were 
imputed based on the guidelines of the TAAQOL. During 
calculation of the scale scores one missing combined-item 
score was allowed for. The missing score is replaced by 
the mean value of the non-missing item scores. Demo-
graphic data of the study and comparison group were 
compared using Chi-square tests for categorical data 
and t-tests for continuous data. We created a distinc-
tion between parents ‘at risk’ and those ‘not at risk’ for 
an impaired HRQOL, based on percentile norms of the 
healthy population.13 A parent in the comparison group 
who scores below the value of the 25th percentile is 
placed in the quarter of the most impaired population. 
We compared the percentage of parents in the disease 
samples scoring below the value of the 25th percentile 
of the norm population, using binomial tests p<0.008 
(0.05/6). We used the Statistical Package for Social Sci-
ences (SPSS) version 14.0.
Results
Participants
The number of participants is shown in Table 1. The 
average response rate was 54%. Overall, the groups had 
similar demographics (p<0.1) except for educational level, 
with a larger proportion of highly educated parents in 
the comparison group (Table 1). Gender distribution in 
Duchenne, sickle cell disease and survivors of a brain 
tumor statistically differed from the comparison group. 
Furthermore, parents of children with sickle cell disease 
and end stage renal disease were more often single and 
had a lower educational level than the comparison 
group. Parents of children with metabolic disease also 
had a lower educational level. Parents of children with 
Down syndrome had more children than the comparison 
group. Furthermore, the age of parents of children with 
asthma, sickle cell disease and metabolic diseases was 
significantly lower than in the comparison group.
Proportion of parents of chronically ill children at risk for HRQOL 
impairment
Table 2 shows the percentages of parents at risk for 
HRQOL impairment for the scales sleep, social function-
ing, daily activities, vitality, and positive and depressive 
emotions. The total group of parents of chronically ill 
children had significantly higher percentages than the 
comparison group, ranging from 35% to 54%. In the dis-
ease groups, parents of children with asthma, metabolic 
disease, and sickle cell disease had significantly higher 
percentages than the comparison group on most scales, 
these parents were therefore considered at risk for an im-
paired HRQOL. Highest percentages of parents with low 
HRQOL scores were found on the scales social function-
ing and depressive emotions.
 
Discussion
The aim of the present study was to determine the 
number of parents with an impaired HRQOL. The results 
show that parents of chronically ill children have a 
seriously low HRQOL almost twice as often as parents of 
healthy children, and are therefore at risk for HRQOL 
impairment. Subgroup analysis shows similar results. 
Although not all differences are statistically significant, 
they indicate a trend towards low HRQOL scores for par-
ents of chronically ill children. The definition of parents 
at risk for an impaired HRQOL was based on the value of 
the 25th percentile of all scales of the comparison group. 
There is no gold standard for a good or bad HRQOL, 
however, this definition is considered to be an appropri-
ate way to differentiate between individuals with higher 
scale scores from individuals with lower scale scores.13 
Our results are in line with other studies describing more 
problems with depression, social and emotional function-
ing in parents of chronically ill children.6,8,9 It should 
be noted that besides the above mentioned difficulties, 
there are also parents who seem to cope well with their 
child’s disease. Both positive and negative determinants 
of HRQOL need to be estimated in future research.
A salient result is that parents of children with metabolic 
disease report a low HRQOL on almost all subscales. This 
might be explained by the hereditary and progressive na-
ture of these diseases (lysosomal storage diseases, organic 
acidurias, mitochondrial respiratory chain defects), with 
an uncertain health status for several children, which 
leads to growing strain and increasing caregiver burden 
over time.14 These care giving demands are extensive 
and are known to influence parental psychological and 
physical health.4
Parents of children with sickle cell disease are also at 
risk for HRQOL impairment. This could also be ex-
plained by their demographics, which differ most from 
the comparison group. In addition, parents of children 
with sickle cell disease in the Netherlands are often 
migrant families, who generally are known to have a lower socioeconomic 
status (SES).To account for SES, we have previously compared this group 
of parents to a SES matched control group15, which showed that parents of 
children with sickle cell disease have a lower HRQOL on the scales daily 
activities, vitality and depressive emotions. 
Some limitations of this study should be addressed. First, although we 
describe ten different groups of parents of chronically ill children, we 
cannot easily generalize the results to all parents of chronically ill children 
as more than 280 ICD-10 diagnoses meet the criteria of chronic childhood 
disease.1 Yet, the outcome of this study indicates an overall burden for par-
ents across disease groups. Second, respondents in this study were mainly 
mothers, thus a more thorough exploration of the HRQOL of fathers is 
desirable. Third, parents in this study had a higher educational level than 
the average Dutch population (Lower: 33%, Intermediate 41%, Higher 25%) 
(16), with the exception of parents of children with end stage renal disease 
and sickle cell disease. The percentage of parents born in the Netherlands 
is also higher than average in the Dutch population. Our expectation is that 
participants in this study had a better SES than average in the Nether-
lands. A lower individual and neighborhood SES level is associated with 
worse health status.17 Therefore in our study we probably show the HRQOL 
of parents with a relatively good SES and health status and presumably 
give an underestimation of the HRQOL impairment. A fourth limitation 
is the average response rate of 54% in the disease groups. We have little 
information on non responders, although the higher educational level in 
comparison to the Dutch average indicates a selection bias towards parents 
with higher educational levels. Finally, we must note that several sample 
sizes were small; these data do however generate the hypothesis of more 
parents being at risk for HRQOL impairment in these groups. 
Clinical and future implications
In conclusion, parents in our study group report seriously impaired HRQOL. 
Parental mental functioning is known to influence their children’s health18 
and adjustment19, both for chronically ill and healthy children. Since 
parents of chronically ill children report higher stress levels than parents 
of healthy children, chronically ill children and their siblings are at higher 
risk for additional health and adjustment problems.
In our opinion pediatricians as well as GP’s should be aware of the impact 
of caring for a chronically ill child on parental HRQOL and of the multitude 
Table 1 Demographics






































 bifida  
n=21
   Gender (Female) 362 (83%) 453 (83%) 78 (87%) 34 (90%) 21 (88%) 42 (74%) 87 (86%) 20 (95%) 90 (76%) 9 (69%) 53 (88%) 19 (91%)
   Married/Partner 386 (87%) 470 (89%) 75 (83%) 32 (84%) 23 (96%) 56 (98%)^ 99(98%)^ 16 (76%) 110 (93%) 12 (92%) 30 (50%)^ 17 (81%)
   Age Years (SD) 43.7 (5.5) 42.0 (6.4)* 42.2 (6.6) 45.8 (5.5)* 45.0 (6.6) 44.0 (5.6) 41.6 (4.9)* 42.8 (3.6) 41.3 (7.0)* 43.4 (5.2) 38.2 (7.3)* 41.0 (6.4)*
Educational level
   Lower 86 (20%) 140 (26%)^ 15 (17%) 9 (24%) 7 (29%) 15 (26%) 20 (20%) 7 (37%)^ 29 (25%) 3 (25%) 30 (50%)^ 5 (24%)
   Intermediate 165 (39%) 220 (41%) 40 (45%) 17 (45%) 8 (33%) 20 (35%) 40 (40%) 10 (52%) 50 (43%) 3 (25%) 22 (37%) 10 (48%)
   Higher 178 (41%) 176 (33%) 33 (38%) 12 (31%) 9 (38%) 22 (39%) 40 (40%) 2 (11%) 38 (32%) 6 (50%) 8 (13%) 6 (28%)
   Children per family 
  Mean (SD) 2.2 (0.8) 2.2 (0.9) 2.2 (0.9) 2.0 (1.0) 2.1 (0.7) 2.2 (1.0) 2.5 (0.9)* 2.1 (0.7) 2.2 (0.9) 2.4 (1.0) 2.3 (1.2) 2.5 (0.8)
  Age chronically ill 
children 
  Yr (SD) - 10.0 (4.5) 10.7 (4.3) 14.6 (4.4) 12.6 (4.4) 11.6 (4.0) 7.3 (1.4) 13.1 (4.1) 8.7 (4.4) 9.8 (4.2) 9.2 (4.5) 9.9 (4.8)
  Time since diagnosis 
  Yr (SD) - 7.8 (4.3) 8.9 (5.0) 8.1 (3.8) 8.0 (5.5) 8.4 (4.3) 7.6 (1.3) 10.9 (5.3) 6.1 (4.0) 10.0 (3.8) 7.5 (4.4) 9.5 (5.1)
Table 2 Percentage of parents of chronically ill children at risk for HRQOL impairment
¹ 25th percentiles of parents of healthy children are not exactly 25%, due to distribution of scale scores. Percentiles approach 25th, ranging from 18th- 31st percentile.
**p<0.008 (0.05/6) for parents in disease group in comparison with parents of healthy children, binomial test








Parents healthy children¹ 433 25% 25% 25% 25% 25% 25%
Chronically ill children 544 42%** 52%** 45%** 41%** 35%** 55%**
Asthma 90 45%** 37% 45%** 40**% 34% 43%**
Survivors of brain tumor 38 42% 40% 16% 19% 24% 49%**
Diabetes 24 42% 50% 42% 33% 29% 46%
Duchenne’s muscular dystrophy 57 40% 58%** 40% 46%** 38% 59%**
Down syndrome 101 33% 53%** 49%** 34% 28% 37%
End stage renal disease 21 44% 61%** 44% 50% 33% 67%**
Metabolic diseases 118 44%** 58%** 56%** 46%** 41%** 69%**
Profound complex handicap 13 33% 55% 40% 50% 55% 40%
Sickle cell disease 61 54%** 55%** 39% 52%** 47%** 75%**
Spina Bifida 21 43% 57% 52% 48% 29% 52%
Introduction
Sickle cell disease (SCD) is a hereditary red blood cell disorder that oc-
curs predominantly in people of African ancestry.1 The clinical picture 
of SCD is characterized by chronic hemolytic anemia and vascular 
occlusion, causing recurrent painful episodes (vaso-occlusive crises) and 
irreversible organ damage.  
Therapeutic options for SCD comprise hematopoietic stem cell trans-
plantation, scheduled blood transfusions and administration of hydrox-
yurea. Hematopoietic stem cell transplantation may have severe side 
effects and therefore most physicians are reluctant to its administra-
tion. Scheduled blood transfusion is another therapeutic option. Unfor-
tunately, it is associated with iron overload, which leads to cardiac and 
endocrine dysfunction if adequate chelation is not installed. Finally, 
hydroxyurea is a therapeutic modality that has proved to reduce the 
rate of painful vaso-occlusive crises in bone. 
The most devastating complication of SCD is cerebral infarction. At the 
age of 18 years, cerebral infarcts are present on MRI scans in one third 
of SCD patients, yet most of these infarcts are not accompanied by focal 
neurological deficits. These so-called silent infarcts appear to be as-
sociated with diminished neurocognitive functioning and an increased 
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of problems parents report. Parental functioning should be part of clinical 
practice in pediatrics. Moreover, attention should be paid to parental func-
tioning as their resilience may be impaired due to sleeping problems and 
problems with vitality and depressive emotions. Family oriented programs 
which have been developed in e.g. psycho-oncology20 should be introduced 
in other disease populations as well. Professionals working with parents 
of chronically ill children should pay attention to the difficulties parents 
experience and provide supportive care if necessary.
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risk of new infarcts.2,3 Neurocognitive deficits, such 
as memory problems or a limited attention span, may 
hamper the development and academic achievement 
of children with SCD. Early detection of neurocogni-
tive deficits is important, providing an opportunity 
for early intervention with adequate support. This 
will have a positive effect on the development and 
academic achievement of these children. This is 
important, because academic underachievement may 
jeopardize full participation of children with SCD in 
society.
The unpredictable course of SCD places a heavy strain 
on affected children and their families. Besides the 
medical problems, most families with a child with 
SCD have to cope with financial and social problems, 
as the majority of these families belong to immigrant 
communities with a lower socio-economic status (SES) 
and 57% of these families are single parented.4 The 
combined effects of neuropsychological dysfunction, 
stress caused by the disease and socio-demographic 
factors may lead to behavioral and emotional prob-
lems in children with SCD. If behavioral and emotion-
al problems arise, it may be difficult for parents and 
professionals involved in the care of these patients 
to distinguish between the causes of these problems. 
However, it is important to differentiate between 
different causes because they may require different 
interventions. 
In August 2007 the AANPAK project (AAndacht voor 
NeuroPsychologische functiestoornissen bij Kinderen 
met sikkelcelziekte) was initiated at the Compre-
hensive Sickle Cell Care Centre of Emma Children’s 
Hospital, Academic Medical Center, in Amsterdam. 
The project aims at identification of neuropsychologi-
cal consequences of SCD. Furthermore, behavioral and 
emotional problems, academic achievement and qual-
ity of life of SCD patients are evaluated. The ultimate 
goal of the project is to offer these patients specific 
care matching their needs. 
The theoretical model of the interrelatedness of all 
these aspects is depicted by the three boxes in Figure 
1. Within this model behavioral and emotional prob-
lems, academic achievement and quality of life are 
regarded as outcomes of neuropsychological func-
tioning, which in itself is regarded as an outcome of 
medical and socio-demographic determinants. Factors 
depicted in the right box of Figure 1 may influence 
neuropsychological functioning (arrow below third 
box directed at middle box).
This theoretical model forms the base for three re-
search questions of the AANPAK project:
1. What are the differences between children with 
SCD and healthy controls (matched for ethnicity 
and socio-economic status) in neuropsychological 
functioning, behavioral and emotional problems, 
academic achievement and quality of life? 
2. What is the association between neuropsychological 
functioning on the one hand and behavioral and 
emotional problems, academic achievement and 
quality of life on the other hand in the total study 
group (containing both children with SCD and 
healthy controls)? 
3. Which biological determinants (medical param-
eters) of neuropsychological functioning can be 
identified in children with SCD?
The data that will be acquired to answer these ques-
tions are given in Table 1. These data will be obtained 
from patients with SCD and from 
healthy controls.
As data collection is currently ongoing and full data 
cannot yet be analyzed, this manuscript presents the 
preliminary results of the frequency and severity of 
Factors Instruments
Medical parameters Cerebral MRI, hematologic parameters
Socio-demographic factors Sex, age, SES, maternal education, ethnic background
Neuropsychological functioning Intelligence, attention, inhibition, visuospatial 
memory, verbal working memory/auditory processing, 
planning/organization, visual-motor integration
Behavioral and emotional problems -  Child Behavior Checklist (CBCL)
-  Teacher Report Form (TRF)
-  Vragenlijst voor Gedragsproblemen bij Kinderen 
(VvGK) [Questionnaire for Behavioral Problems in 
Children]. 
Academic achievement CITO scores [Dutch Secondary School placement exam 
scores]
Quality of Life Kidscreen
Table 1. Factors and corresponding instruments used in the AANPAK project
Table 2. Proportion of SCD children with problem scores within 
the clinical range on the TRF broad-band scales. 
* Significant difference at p<0.01 between children aged 6-11 
and 12-18.
** Significant difference at p<0.05 between children with severe 
and moderate form of SCD.
Internalizing  Externalizing
 n % n %
Sex 
   Male (n=49) 7 14 10 20
   Female (n=27) 5 19 5 19
Age in years
   6-11 (n=43) 5 12* 8 19
  12-18 (n=33) 7 21 7 21
Disease severity
   Severe form of SCD   
   (n=61)
12 20** 10 16
   Moderate form  
   of SCD    (n=15)
0 0 5 33




















behavioral and emotional problems in children with 
SCD, as reported by their teachers.
Methods
Patients
Patients aged 6-18 years with SCD (HbSS, HbS-β0-
thalassemia, HbS-β+-thalassemia or HbSC) who were 
treated at the Comprehensive Sickle Cell Care Centre 
of Emma Children’s Hospital, Academic Medical Cent-
er, in Amsterdam were eligible for inclusion. After 
parental informed consent was given, questionnaires 
were sent to their teachers from August 2007 onwards.
Instruments
The Teacher Report Form (TRF)5 was used. This ques-
tionnaire provides scores on two broad-band scales: 
Internalizing (Anxious/Depressed scale, Withdrawn/
Depressed scale and Somatic Complaints scale) and Ex-
ternalizing (Rule-breaking Behavior scale and Aggres-
sive Behavior scale). Adequate psychometric properties 
for this rating scale have been established. 
T-scores higher than 63 (above the 90th percentile) 
represent problems within the clinical range and indi-
cate that a child needs professional help. In the Dutch 
norm group 9% of the children had scores within the 
clinical range on both broad-band scales.
Statistics
Frequency distributions were calculated to determine 
the number of patients with problem scores within 
the clinical range. The chi-square test was used to de-
termine differences according to sex, age and disease 
severity.  
RESULTS
124 Children with SCD were eligible for inclusion. Up 
to January 2008, 76 questionnaires were returned 
(response rate 61%). The questionnaires concerned 49 
boys and 27 girls (mean age 11.5 years, SD 3.5). Sixty-
one (80%) children have a severe form of SCD (HbSS or 
HbS-beta0-thalassemia) and 15 (20%) children have a 
moderate form of SCD (compound heterozygous form: 
HbSC or HbS-beta+-thalassemia). 
 In Table 2 the proportion of children with clinical 
problem scores is given for the two broad-band scales. 
In the total group 16% of patients have internalizing 
problems and 20% of patients have externalizing 
problems. These proportions are significantly higher 
than those in the Dutch norm group. No differences 
between boys and girls were found.
In patients above 12 years a significantly higher pro-
portion had internalizing problems (21%) as compared 
with in younger patients (12%). The proportion of 
patients with a severe form of SCD with internalizing 
problems (20%) was significantly higher than that in 
patients with a moderate form of SCD (0%).
Discussion
First preliminary results show an increased frequency 
of both internalizing and externalizing problems, 
especially in adolescents with SCD. However, these 
preliminary results are obtained only by teachers´ re-
ports and do not take the opinion of the parents into 
account. When questionnaires that are filled in by the 
parents are available this may confirm or change the 
findings. 
Moreover, since these preliminary results are derived 
exclusively from children with SCD, we cannot yet 
determine whether behavioral and emotional prob-
lems are a specific consequence of SCD or whether 
they are a result of the socio-demographic situation of 
these children. This will be analyzed when data from 
healthy controls are available.
Conclusions
These findings indicate that according to the teach-
ers´ report almost 1 out of 5 children with SCD has 
behavioral and /or emotional problems within the 
clinical range and needs professional help. Children 
with a severe form of SCD and older children (12-18 
years) seem to be at increased risk of development of 
internalizing problems.
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Introduction
Gastroesophageal reflux (GER) is present in all children. Typical GER 
symptoms, such as regurgitation, are normally mild and relatively 
harmless and therefore considered to be physiological.1 However, in 
a subgroup of infants, GER can cause more severe symptoms, such as 
feeding problems and failure to thrive, as well as complications, such as 
esophagitis. It is then referred to as GER disease.
The acidity of GER episodes is thought to be a major pathophysiologi-
cal factor in the development of these symptoms and complications. 
In infants, gastric contents are buffered by milk in the postprandial 
period.2,3 Consequently, GER is likely to be weakly acidic (4 < pH < 7) in 
the first hour after a meal, while acid GER (pH<4) occurs more often in 
the late postprandial period.4 
In all age groups, gastric distension induced (e.g. after a meal) transient 
lower esophageal sphincter relaxation (TLESR) is the most important 
underlying mechanism of GER.5-7 
We previously studied the effect of left/right body positioning on GER 
and TLESR triggering in premature infants and found that right-lateral 
positioning (RLP) was associated with an increased proportion of liquid 
reflux compared to left lateral positioning (LLP).8 This was probably 
due to the presence of gastric contents above the level of the esoph-
agogastric junction in the latter position, as demonstrated radiologi-
cally by Ewer and colleagues.9 However, a more interesting finding of 
our previous study, was that the overall triggering of TLESRs following 
feeding was significantly greater and gastric emptying (GE) of the feed 
significantly faster in the RLP.
The aim of this study was to investigate the effects of changing body 
position on the triggering of TLESRs, GER and GE, in order to identify 
a positioning regime that could both promote GE and decrease the 
number of acid GER episodes occurring during the late postprandial 
period, when GER becomes more acidic.
Methods
Subjects and baseline characteristics (Table 1)
We studied 10 preterm infants (7 male; 3 female) who did not experience 
any symptoms related to GER or other gastrointestinal diseases and 
were healthy apart from their prematurity. All subjects were studied 
at the Women’s and Children’s Hospital in Adelaide, Australia. The sub-
jects had a median gestational age of 31.5 (range: 27-36) weeks. Postnatal 
age at commencement of the study was 23 (11-62) days resulting in a 
corrected age of 36 (33-38) weeks). The median weight at the time of the 
study was 2415 (2130 – 2800) g. For ethical reasons, all infants had to 
receive at least one of their daily feeds by gavage. The parents or guard-
ians gave written informed consent before the commencement of each 
study and the protocol was approved by the Research Ethics Committee 
of the Women’s and Children’s Hospital.
Measurement Techniques
Esophageal impedance and manometry 
A combined multichannel intraluminal impedance and manometry 
catheter (outer diameter: 2 mm) that also allowed for gavage feeding 
was developed for the purpose of this study (Figure 1). The assembly 
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GERD: gastroesophageal reflux disease
LES: lower esophageal sphincter
LLP: left lateral position 
PPH: postprandial hour 
RLP: right lateral position 
TLESR: transient lower esophageal sphincter relaxation
Figure 1: Catheter design. Imp: impedance segment; LES: lower esophageal sphincter
consisted of a water-perfused manometric sleeved catheter. Electrode 
rings allowed for the recording of 5 segments of intraluminal imped-
ance throughout the esophagus. A feeding lumen was incorporated with 
its opening at the distal end of the assembly.
Gastric emptying rate
Gastric emptying rate was determined with the 13C-Na-octanoate breath 
test. This test has been described in detail elsewhere and has proved 
to be a reliable and reproducible non invasive means of testing gastric 
emptying.10,11
Experimental protocol
All infants were studied twice on two consecutive days and subjected to 
two positioning protocols in a randomized cross-over fashion (Figure 2). 
The assembly was passed transnasally into the stomach and positioned 
with the sleeve straddling the LES. The infants were then positioned 
in either the right lateral position (RLP) or left lateral position (LLP) 
and gavage fed their normal feed (expressed breast milk or formula). 
Feed volume was identical for both studies and the feed was infused 
by the same research nurse, who tried to keep the infusion velocity 
constant. One hour following the end of the feed, the infant’s position 
was changed to the opposite lateral side and manometry and impedance 
recordings continued for a further two hours. 
Data analysis
All details that could identify the subject and all information regarding 
the protocol were removed from each tracing before analyses. Manom-
etry and impedance tracings were analyzed for GER and TLESRs using 
established criteria.12,13 Manometry and impedance data were compared 
between the RLP and the LLP. To this end, data from the 1st hour of the 
RLP first protocol were combined with the 2nd and 3rd hour of the LLP 
first protocol and these were compared with the data from the 1st hour 
of the LLP first protocol and 2nd and 3rd hour of the RLP first protocol. 
In addition, all data were compared between the two protocols and 
between the first and second postprandial hour (PPH) in both protocols.
Statistical analysis
Normally distributed data are presented as means ± SD and are com-
pared between the protocols or between sides using the paired t-test. 
Non parametric data are presented as median (range) and are compared 
with the Wilcoxon’s matched pairs signed ranks test. A p-value of less 
then 0.05 was considered statistically significant.
Results
Feeding volumes and time
Feed volumes given to the infants were identical on both study days, 
ranging from 50 - 80 ml between infants (median: 67.5 ml) Administra-
tion of the feed took 12.3 (7.5–36.2) minutes by hand-driven syringe. The 
time taken to administer feeds was similar in the two protocols (RLP 
first: 13.1 (7.5-36.2) min vs. LLP: 12.3 (8.0-25.8) min., p=0.770). 
Table 1: Demographics and randomization.
No: studynumber; PMA: post menstrual age (wks); PNA: post natal age (days); BW: birthweigt (g); Weight: weight at first studyday (g); EBM: expressed breast milk; Volume: volume 
of feed (ml); Frequency: feeds/day; 1st protocol: protocol followed during first study day. RLP: right lateral position; LLP: left lateral position.
No Sex PMA PNA BW Weight Feed Volume Frequency 1st protocol
1 Male 33 24 1950 2500 Formula 70 6 RLP first
2 Female 28 45 1340 2330 EBM 60 7 LLP first
3 Male 33 21 1730 2210 EBM 65 6 RLP first
4 Male 36 14 2450 2630 EBM 70 6 LLP first
5 Female 29 44 1205 2330 EBM 50 7 RLP first
6 Male 29 52 1370 2520 Formula 70 6 LLP first
7 Female 27 62 1050 2530 Formula 70 6 RLP first
8 Male 30 22 1920 2130 Formula 55 7 RLP first
9 Male 34 13 2830 2800 EBM 80 6 LLP first
10 Male 34 11 2370 2320 Formula 65 7 LLP first
Figure 2: Experimental protocol. Note that all infants were studied according to both 
protocols in a cross over fashion. The feeding time was dependent on the volume of feed 
primarily. RLP: right lateral position; LLP: left lateral position; PPH: postprandial hour
Figure 3: Percentages of liquid, mixed and gas GER attributing to the total number 
of GER episodes on the LLP and the RLP. (Absolute number of GER episodes given in 
parentheses). GER: gastro-esophageal reflux; LLP: left lateral position; RLP right lateral 
position. * p<0.01; ** p<0.005, Wilcoxon’s matched pairs signed rank sum test.
RLP vs. LLP
More TLESRs and GER episodes were triggered while infants were in 
the RLP compared to the LLP [TLESRs: 9.5 (3.0-19.0) vs. 5.0 (3.0-17.0), 
respectively, p=0.020; GER episodes: 11.5 (6.0-24.0) vs. 7.0 (5.0-17.0), 
respectively, p=0.004]. Liquid GER episodes were more frequent in 
the RLP compared to LLP [9.5 (6.0-22.0) vs. 2.0 (0.0-5.0), respectively, 
p=0.002]. In contrast, the number of gas and mixed GER episodes was 
significantly lower in the RLP compared to LLP [gas: 0.0 (0.0-4.0) vs. 
4.5 (1.0-10.0), respectively, p=0.012; mixed: 0.0 (0.0-2.0) vs. 1.0 (0.0-3.0) 
respectively, p=0.031]. The relative contribution of liquid, mixed and 
gas GER to the total number of GER episodes was therefore significantly 
different between the two positions (Figure 3).
RLP first protocol vs. LLP first protocol (Table 2)
The occurrence of TLESRs, as well as the number of GER episodes and 
the type of GER triggered over the study period differed between the 
two protocols (Figure 4). All data for the two protocols are given in 
Table 2. 
First vs. second postprandial hour 
During the RLP first protocol, the number of TLESRs and the number 
of liquid GER episodes were significantly higher, and gas GER episodes 
lower in the first hour (RLP) compared to the second (LLP) (Figure 4 & 
Table 3). During the LLP first protocol the number of liquid reflux epi-
sodes was significantly lower while the number of TLESRs and gas GER 
episodes was similar in the first hour (LLP) compared with the second 
(RLP) (Figure 4 and Table 3).
Gastric Emptying
Gastric half emptying time (GEt1/2) was significantly faster during the 
RLP first protocol when compared to the LLP first protocol (37.0 +/- 21.1 
vs. 61.2 +/- 24.8, p=0.006 (Figure 5 and Table 4; online)). 
RLP first protocol LLP first protocol p value
Overall TLESR 7.5 (4.0-21.0) 9.0 (2.0-15.0) NS (0.193)
All GER 9.0 (5.0-28.0) 7.0 (3.0-15.0) NS (0.322)
Liquid GER 6.0 (2.0-13.0) 7.0 (2.0-13.0) NS (0.469)
Mixed GER 0.0 (0.0-5.0) 0.5 (0.0-2.0) NS (0.813)
Gas GER 4.0 (1.0-10.0) 1.0 (0.0-6.0) NS (0.055)
1st PPH RLP: LLP:
TLESR 4.0 (2.0-8.0) 2.5 (0.0-6.0) 0.031
All GER 5.5 (2.0-15.0) 2.5 (1.0-5.0) 0.004
Liquid GER 5.5 (2.0-13.0) 2.0 (0.0-4.0) 0.004
Mixed GER 0.0 (0.0-2.0) 0.0 (0.0-2.0) NS (0.438)
Gas GER 0.0 (0.0-2.0) 0.5 (00-2.0) NS (0.313)
2nd PPH LLP: RLP:
TLESR 2.0 (1.0-5.0) 3.0 (1.0-7.0) NS (0.250)
All GER 2.5 (1.0-6.0) 4.0 (1.0-8.0) NS (0.109)
Liquid GER 0.0 (0.0-1.0) 3.5 (1.0-8.0) 0.004
Mixed GER 0.0 (0.0-2.0) 0.0 (0.0-1.0) NS (0.500)
Gas GER 2.5 (0.0-6.0) 0.0 (0.0-1.0) 0.016
3rd PPH LLP: RLP:
TLESR 2.0 (0.0-8.0) 2.0 (0.0-6.0) NS (0.922)
All GER 2.0 (0.0-8.0) 1.5 (0.0-7.0) NS (0.742)
Liquid GER 0.0 (0.0-1.0) 1.0 (0.0-3.0) 0.016
Mixed GER 0.0 (0.0-1.0) 0.0 (0.0-1.0) NS (0.500)
Gas GER 1.0 (0.0-7.0) 0.0 (0.0-4.0) NS (0.164)
Table 2. Median (range) number of TLESRs and GER episodes. Comparison between the two protocols. 
Differences expressed as p-value (Wilcoxon’s matched pairs signed rank sum test). TLESR: transient lower esophageal sphincter relaxation; GER: gastroesophageal reflux; RLP: right 
lateral position; LLP: left lateral position; PPH: postprandial hour: NS: statistically not significantly different
Figure 4: Total number of TLESRs and GER episodes (liquid, mixed and gas) over time. 
X-axis is comprised of 10 minute periods, where 10 stands for 0-10 minutes, 20 for 10-20 
minutes etc. GER: gastro-esophageal reflux; LLP: left lateral position; RLP right lateral 
position.
Discussion
This study shows that positioning healthy infants in the right lateral 
position (RLP) for the first postprandial hour (PPH) and in the left 
lateral position (LLP) afterwards virtually eliminates liquid GER in the 
late postprandial period when gastric contents are acidic. Overall, we 
found that more GER episodes were triggered in the RLP. This increase 
during RLP is in accordance with a recent study of healthy infants 
either in the RLP or the LLP, while we showed that more TLESRs are 
triggered in the RLP as compared with the LLP.8 
In the present study, we have also shown that the proportion of liquid 
GER is much greater in the RLP as compared with the LLP (87% vs. 26%). 
This difference was not only present in the first PPH, but particularly 
became clear after the change to the left side position. Turning infants 
from the LLP to the RLP was associated with a rapid increase in occur-
rence of liquid GER episodes. On the other hand, turning the infants 
from the RLP to the LLP stopped liquid GER and caused triggering of 
gas GER. It is now clear that this change in reflux type relates to the 
anatomical configuration of the stomach which makes it more likely 
that liquid will pool at the level of the EGJ in the RLP.9 
The current study has demonstrated that the change from left to right, 
as well as changing the type of GER triggered, also increased the total 
number of TLESRs and GER triggered. The opposite change from right 
to left had the opposite effect. In a dog model, Franzi et al showed that 
the threshold for distension-induced triggering of TLESRs is lowest in 
the region of the stomach just distal to the esophagogastric junction.16 It 
could be argued that pooling of fluid at the EGJ region associated with a 
change to the RLP causes localized distension of the sub-cardiac region 
resulting in increased triggering of TLESRs. The opposite change to the 
LLP would result in pooling of fluid in the corpus and, although gas 
above the liquid would also distend the region just distal to the esoph-
agogastric junction, the subsequent triggering of TLESRs and gas reflux 
would lead to greater depressurisation of the gastric lumen.14 
Reduced capacity to vent gas and depressurise the stomach in the RLP 
could explain the rapid rise in TLESRs seen after the posture change 
to the right side. However, it should also be noted that GE rate also 
rapidly increased with the position change to the right. Although this 
increase in GE should assist depressurising the stomach, the triggering 
of TLESRs and GER is still increased. The opposite is the case with the 
position change to the LLP, during which the triggering of TLESRs and 
GER decreases, whilst at the same time GE slows.
Our previous studies in premature infants with and without GERD indi-
cated that the triggering of acid reflux in association with TLESRs was 
significantly greater in infants with GER disease.5,6 Therefore, control 
of acid GER in the late postprandial period may be more therapeutically 
relevant than reducing non-acid GER in the early postprandial period. 
In addition, it is a widely held view that delayed GE is a feature of GERD 
and that delayed GE also exacerbates reflux in GERD patients(17-19). 
The objective of any treatment for GERD should therefore be to reduce 
acid GER and accelerate GE. The current study indicates that this can 
be achieved in healthy infants by placing them in the RLP for one hour 
followed by a position change to the LLP. 
In conclusion, our study showed that positioning a healthy infant on 
the RLP for the first PPH and turning it to the LLP afterwards, virtu-
ally eliminates all liquid GER in the late postprandial period, when acid 
GER occurs.
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Table 3: Median (range) number of TLESRs and GER episodes. Data given for 1st PPH and 
2nd PPH.
Difference between 1st PPH and 2nd PPH expressed as p-value (Wilcoxon’s matched pairs 
signed rank sum test). TLESR: transient lower esophageal sphincter relaxation; GER: 
gastroesophageal reflux; RLP: right lateral position; LLP: left lateral position,; PPH: 
postprandial hour.
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Healthy humans eat to compensate for continuous 
loss of energy and nutrients due to ongoing mobiliza-
tion and utilization of metabolic substrates from the 
tissues. Besides maintaining this status quo, children 
need to ingest extra amounts of energy and metabolic 
building blocks for growth (linear and body weight) 
and development (i.e. metabolic maturation of organs).
In critical illness or after major surgery, energy and 
glucose are mobilized from fat tissue and glycogen 
storage pools. Proteins (predominantly from muscle) 
are degraded into amino acids that are funneled into 
the gluconeogenesis pathway, and serve as building 
blocks for new proteins (e.g. immunologic response, 
tissue repair). As apposed to fat and glucose, there is 
no resting storage pool of protein in the body. Since 
all proteins are functional (be it structural or soluble), 
loss of protein leads to loss of organ function (e.g. 
muscles, visceral organs) and thus of the organism as a 
whole. In critical illness, protein-energy malnutrition 
increases mortality and morbidity, number of ventila-
tor days and length of stay (LOS) (1,2). Recent studies 
show that no less than 25% of patients on a Pediatric 
Intensive Care Unit (PICU) are malnourished at the 
time of admission, with risk of further deterioration 
of nutritional status during hospitalization (3,4). Inad-
equate feeding during the first few days of PICU admis-
sion accounts for almost 50% of cumulative caloric 
and protein deficits (5). Especially young infants and 
children after cardiac surgery, due to higher metabolic 
demands and fluid restriction, respectively, may be at 
risk for undernutrition (6). In a recent survey on our 
PICU, we found that caloric goals were met only on day 
5 of admission, while the mean daily protein prescrip-
tion remained 75% of age related targets during the 
entire admission period (maximum 10 days) (7).
Chronic illness is characterized by adaptive meta-
bolic responses. It is well known that children with 
cystic fibrosis (CF) have less net protein anabolism 
than healthy individuals, resulting in stunted linear 
growth. However, this protein energy malnutrition has 
adverse effects on respiratory muscle strength, ventila-
tory drive, and immune defense mechanisms (8,9). 
It is evident that in all different phases of illness there 
is a constant change of metabolic needs that have to be 
met by different amounts and composition of nutri-
tion. In fact, clinical nutrition can be used to partly 
counteract disease-related catabolic effects by manipu-
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lation of breakdown and synthesis rates of tissues, via direct effect or by 
changes in serum levels of catabolic (e.g. cortisol) and anabolic hormones 
(e.g. insulin).
In children with acute disease (post cardiac surgery with extracorporeal 
circulation) and chronic disease (CF), we have observed the short-term 
effects of high (5 g·kg-1·d-1) versus normal dietary protein intake on 
whole-body protein synthesis and breakdown rates, and net protein 
balance (10,11). These effects on whole body protein metabolism were 
measured using stable isotopic infusion technique, which is explained 
elsewhere in detail (11). We also measured differences in serum concen-
trations of key anabolic and catabolic hormones in both disease states.
Critical illness
In a study in children, after cardiac surgery with extracorporeal circula-
tion, we included 24 children, aged 3-48 months, with complex congeni-
tal heart defects (10). After allocation to either arm of the protocol (2 
versus 5 g·kg-1·d-1 dietary protein intake), the study diets were started 
approximately 4 hours after surgery via a nasogastric tube (Fig.1). The 
diets consisted of a mixture of carbohydrate powder, fat emulsion, and 
whey protein powder, dissolved in water. Via the continuous drip-feed-
ing the carbohydrate intake was held at a constant rate, in order to avoid 
great fluctuations of endogenous insulin secretion. The protein intake 
was varied according to protocol (2 and 5 g·kg-1·d-1, respectively), with 
the remaining non-protein calories supplied by fat.
After determination of background enrichment of natural isotopes, 
primed stable isotope infusion was started on the first postoperative day. 
On the second postoperative day, blood and breath samples were taken at 
regular intervals for determination of isotopic enrichment, and plasma 
concentrations of insulin, glucagon, and cortisol, and (nor)epinephrine. 
Isotopic kinetics of the normal protein (2 g·kg-1·d-1, NP) and high protein 
(5 g·kg-1·d-1, HP) groups showed no statistically significant differences 
in whole-body protein synthesis. However, in the HP group we observed 
a drastic reduction of endogenous protein breakdown with a consequent 
11-fold more positive whole body protein balance, compared to the NP 
group. Moreover, patients in the HP group had a significantly higher 
serum concentration of the anabolic hormone insulin, and a lower 
concentration of the catabolic hormone cortisol. We concluded that in 
children after cardiac surgery, high dietary protein intake decreases 
short-term whole-body proteolysis, resulting in better net protein bal-
ance, potentially by means of increased insulin secretion, and decreased 
the plasma concentration of cortisol.
Chronic illness
In another study, we administered a 4-day liquid diet via a gastric 
continuous drip in eight chronically catabolic, stunted children with 
CF aged 7-12 years (11). The caloric intake of the study diet was 200% of 
the baseline measured energy expenditure, and contained a mixture of 
carbohydrate powder, fat emulsion, and protein powder. Via the continu-
ous drip-feeding the carbohydrate intake was held at a constant rate, in 
order to avoid fluctuations of endogenous insulin secretion. The protein 
intake was varied according to protocol (1.5, 3 and 5 g·kg-1·d-1, respec-
tively), with the remaining non-protein calories supplied by fat. On the 
fourth day whole body protein synthesis and breakdown were measured, 
by using stable isotope technique. The entire protocol was repeated twice 
in each child with a wash out period of six weeks, so that at the end of 
the study period, all children had been exposed to diets containing 1.5, 3 
and 5 g·kg-1·d-1 protein. 
In this study, we observed a progressive increase of whole-body protein 
synthesis of 30% with increasing dietary protein intake (1.5, 3 and 5 
g·kg-1·d-1, respectively). On the other hand, whole-body protein break-
down differed not significantly between the diets, resulting in a higher 
net protein balance. There was a trend of higher serum concentrations 
of insulin and glucagons in the HP diet, compared to the NP diet.
Future research
In conclusion, we were able to improve whole-body protein balance in 
both study groups with supra-physiologic amounts of dietary protein 
intakes. However, in the post cardiac surgery patients, this was achieved 
by inhibiting proteolysis, whereas in the CF group protein synthesis was 
enhanced. In both study groups higher intakes of protein led to higher 
serum concentrations of insulin. Indeed, milk proteins have insulino-
tropic properties, of which the whey fraction contains the predominat-
ing secretagogue. In the cardiac surgery patients, there were also lower 
cortisol levels after the HP diet, compared to the NP diet.
These results show that protein balance can be improved in both acute 
and chronic illness by high protein diets. This is not the result of merely 
replenishing certain existing deficits with extra protein, but represents 
a remodeling action on the (hyper)metabolic stress response to illness in 
its different phases. 
In future research, we would like to investigate whether this remodeling 
is a direct action of (a subset of) amino acids, or is induced via secretion 
of insulin.
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Verkort IB-tekst: 
Samenstelling: CARNITENE bevat L-carnitine en is verkrijgbaar als: CARNITENE tabletten, 330 mg, CARNITENE drank 1 gram/ 10 ml (100 mg/ml) CARNITENE injectievloeistof, 1 gram / 5 ml
(200 mg/ml). Indicaties: Primaire (systemische) carnitine deficiënties, Eigenschappen: CARNITENE, L-carnitine (y-trimethylamino-B-hydroxybutyraat) is een lichaamseigen stof. L-carnitine wordt
bij de mens hoofdzakelijk gevormd door endogene synthese uit lysine en methionine in de lever en de nier, maar kan ook verkregen worden uit de voeding. De L-isomeer, is biologisch actief en
speelt een essentiële rol zowel in het lipide metabolisme als in het metabolisme van ketonlichamen en vertakte-keten aminozuren. L-carnitine is noodzakelijk voor het transport van lang-keten vet-
zuren over het binnenmembraan van de mitochondria naar de mitochondriale matrix, waar de B-oxidatie plaatsvindt met als resultaat productie van ATP. Bij een systemische carnitinedeficiëntie is
er een tekort aan L-carnitine in het serum en in een of meerdere weefsels. De meest voorkomende symptomen van een systemische carnitine-deficiëntie zijn: 1. manifestatie begint in de eerste
levensjaren, 2. acute episoden van encefalopathie (braken gevolgd door een progressief verlopende stupor, verwarring en coma) die geassocieerd wordt met leverfunctie stoornissen, zeer vaak
geïnduceerd door een verminderde opname en/of fysieke inspanningen, 3. progressieve spierfunctie achteruitgang, 4. vetopstapeling in de spier- en andere weefsels (lever, nier enz.), 5. sterk ver-
laagde carnitinespiegels zowel in het bloed als in weefsel. Laboratorium onderzoek toont aan een hypoglykemie, een verhoging van CPK en leverenzymen in het serum, verhoogde ketose tijdens
vasten, EMG (electromyogram) veranderingen. 
De rationale om patiënten met een carnitinedeficiëntie te behandelen met L-carnitine ligt in het normaliseren van de weefselspiegels en/of deze in overeenstemming te brengen met de behoefte van
het organisme op dat moment en de spierfunctie te herstellen. Waarschuwingen voorzorgsmaatregelen: Daar L-carnitine slechts in geringe mate gemetaboliseerd wordt, en als L-carnitine door
de nier wordt uitgescheiden, wordt bij patiënten met een verminderde nierfunctie (GFR < 10 ml/min) aangeraden de medicatie te doen plaatsvinden op geleide van plasmaspiegels. Toediening van
een hoge orale doses Levocarnitine gedurende lange perioden wordt niet aanbevolen in patiënten met een chronische nierinsufficiëntie, die gedialyseerd worden. Er vindt dan een cumulatie plaats
van belangrijke metabolieten zoals trimethylamine (TMA) en trimethylamine-N-oxide (TMAO) omdat deze niet in voldoende mate door de nier geëlimineerd kunnen worden. Dit verschijnsel treedt niet
in dezelfde mate op na intraveneuze toediening. Een cumulatie van TMA is nadelig omdat hiermee de stikstofhoudende afval producten die door dialyse verwijderd worden, verhoogd wordt. Boven-
dien worden de verhoogde TMA spiegels geassocieerd met neurofysiolosche effecten. De onvolledige eliminatie van TMA kan resulteren in de ontwikkeling van een vislucht geur. Indien overwogen
wordt om deze patiënten levocarnitine toe te dienen wordt aangeraden dit intraveneus te doen. Gebruik in de zwangerschap: Over het gebruik van deze stof in de zwangerschap bij de mens
bestaan onvoldoende gegevens om de mogelijke schadelijkheid te beoordelen. Er zijn tot dusver geen aanwijzingen verkregen voor schadelijkheid bij dierproeven. Bijwerkingen: Een lichte vorm
van diarree bij sommige patiënten is na hoge orale toediening gerapporteerd. Dosering: De dosering wordt bepaald door de mate van carnitine deficiëntie. Indien mogelijk moet op geleide van car-
nitine bloed-/weefselspiegels behandeld worden. 
Primaire (systemische) carnitine deficiëntie. Aanbevolen wordt de volgende dosering per os per dag:
Zuigelingen 100-150 mg/kg lichaamsgewicht 
Kinderen tot 12 jaar 50-100 mg/kg lichaamsgewicht 
Volwassen en kinderen boven de 12 jaar 20-40 mg/kg lichaamsgewicht 
In de praktijk betekent dit dat de gemiddelde dosering per os per dag ligt voor: 
Zuigelingen 1 gram 
Kinderen tot 12 jaar 2 gram 
Volwassen en kinderen boven de 12 jaar 2-4 gram (in twee a drie giften) 
Indien er geen verbetering optreedt in de klinische en biochemische symptomen/spierzwakte, kan de dosering verhoogd worden tot 15 gram per dag, gedurende korte tijd. De CARNITENE injectie-
vloeistof is bedoeld voor acute gevallen en wanneer toediening per os niet mogelijk is. De injectievloeistof dient langzaam (3 minuten) intraveneus toegediend te worden. Met de intraveneuze vorm
kan met lagere doseringen (maximaal 30 mg/kg lichaamsgewicht per dag) worden volstaan, gezien de volledige beschikbaarheid van de stof na i.v. toediening ten opzichte van < 10% na orale toe-
diening. 
Onderverdeeld naar leeftijd betekent dit per dag: 
Zuigelingen maximaal 30 mg/kg lichaamsgewicht
Kinderen tot 12 jaar maximaal 20 mg/kg lichaamsgewicht
Volwassen en kinderen boven de 12 jaar maximaal 10 mg/kg lichaamsgewicht
Registratie: Ingeschreven in het register onder: 
RVG 11192 CARNITENE sigma tau injectievloeistof 1 gram 
RVG 11193 CARNITENE sigma tau drank 1 gram 
RVG 11194 CARNITENE sigma tau tabletten 330 mg 
Registratiehouder: Sigma Tau Ethifarma B.V., Postbus 10072, 9400 CB  Assen. Voor inlichtingen: Sigma Tau Ethifarma B.V.,
Postbus 10072, 9400 CB  Assen, telnr. 0592 333000.
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